Details

Autor(en) / Beteiligte

• Camell, Christina D
• Yousefzadeh, Matthew J
• Zhu, Yi
• Prata, Larissa G P Langhi
• Huggins, Matthew A
• Pierson, Mark
• Zhang, Lei
• O'Kelly, Ryan D
• Pirtskhalava, Tamar
• Xun, Pengcheng
• Ejima, Keisuke
• Xue, Ailing
• Tripathi, Utkarsh
• Espindola-Netto, Jair Machado
• Giorgadze, Nino
• Atkinson, Elizabeth J
• Inman, Christina L
• Johnson, Kurt O
• Cholensky, Stephanie H
• Carlson, Timothy W
• LeBrasseur, Nathan K
• Khosla, Sundeep
• O'Sullivan, M Gerard
• Allison, David B
• Jameson, Stephen C
• Meves, Alexander
• Li, Ming
• Prakash, Y S
• Chiarella, Sergio E
• Hamilton, Sara E
• Tchkonia, Tamara
• Niedernhofer, Laura J
• Kirkland, James L
• Robbins, Paul D

Titel

Senolytics reduce coronavirus-related mortality in old mice

Ist Teil von

• Science (American Association for the Advancement of Science), 2021-07, Vol.373 (6552)

Ort / Verlag

United States: The American Association for the Advancement of Science

Erscheinungsjahr

2021

Quelle

American Association for the Advancement of Science

Beschreibungen/Notizen

• The COVID-19 pandemic has revealed the pronounced vulnerability of the elderly and chronically ill to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced morbidity and mortality. Cellular senescence contributes to inflammation, multiple chronic diseases, and age-related dysfunction, but effects on responses to viral infection are unclear. Here, we demonstrate that senescent cells (SnCs) become hyper-inflammatory in response to pathogen-associated molecular patterns (PAMPs), including SARS-CoV-2 spike protein-1, increasing expression of viral entry proteins and reducing antiviral gene expression in non-SnCs through a paracrine mechanism. Old mice acutely infected with pathogens that included a SARS-CoV-2-related mouse β-coronavirus experienced increased senescence and inflammation, with nearly 100% mortality. Targeting SnCs by using senolytic drugs before or after pathogen exposure significantly reduced mortality, cellular senescence, and inflammatory markers and increased antiviral antibodies. Thus, reducing the SnC burden in diseased or aged individuals should enhance resilience and reduce mortality after viral infection, including that of SARS-CoV-2.